dicompare schema: MY-RADS Myeloma Whole-Body MRI Guidelines (v1.0)

Myeloma Response Assessment and Diagnosis System (MY-RADS) guidelines for whole-body MRI in myeloma as reported in Messiou et al. 2019. Messiou C, Hillengass J, Delorme S, et al. Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology. 2019;291(1):5-13. https://doi.org/10.1148/radiol.2019181949 The MY-RADS imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma and allow response assessment. **Protocol Timing:** - Core clinical protocol: ~30 minutes - Comprehensive protocol: ~45-50 minutes **Key Rationale:** - Wide anatomic coverage (vertex to knees, >100 cm) is essential because **50% of lesions would be missed by imaging the spine alone** - Whole-body MRI provides the largest rise in quality-adjusted life years compared with CT or FDG PET/CT - Contrast-enhanced imaging is NOT essential for bone marrow disease assessment **Disease Patterns:** - **Normal**: Age-appropriate fatty marrow signal - **Focal**: Discrete lesions >5 mm with abnormal signal - **Diffuse**: Generalized marrow infiltration (requires trephine confirmation) - **Focal-on-diffuse**: Focal lesions superimposed on diffuse background infiltration - **Micronodular/Variegated**: Tiny nodular areas (≤5 mm) with preserved normal marrow between them **Soft Tissue Disease:** - **Paramedullary**: Soft tissue disease in direct continuity with bone marrow disease - **Extramedullary**: Soft tissue disease NOT in continuity with bone marrow (e.g., ischiorectal fossa, pancreas) **ADC Interpretation Thresholds:** - Normal bone marrow: <600-700 µm²/s - Viable tumor: 700-1400 µm²/s - Treated/necrotic disease: ≥1400 µm²/sThis is a dicompare validation schema. View, browse, and use it at https://dicompare.neurodesk.org/schema/MY-RADS_Myeloma_v1.0.